Claims for Patent: 9,925,151

Summary for Patent: 9,925,151

Title:	Cladribine regimen for treating multiple sclerosis
Abstract:	The present invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy.
Inventor(s):	Brentzel, Jr.; H. James (Marshfield, MA), Lopez-Bresnahan; Maria (Lincoln, MA), Ammoury; Nazih (Prevessin-Moens, FR)
Assignee:	MERCK SERONO SA (Coinsins, Vaud, CH)
Application Number:	12/301,083
Patent Claims:	1. A method of treating patients suffering from multiple sclerosis and who are refractory to at least one conventional therapy for multiple sclerosis with interferon beta-1a, interferon beta-1b, or glatiramer acetate, said method comprising administering IFN-.beta. in combination with orally administered Cladribine to a patient refractory to at least one conventional therapy for multiple sclerosis with interferon beta-1a, interferon beta-1b, or glatiramer acetate according to the following sequential steps: (i) an induction period wherein Cladribine is administered and wherein the total dose of Cladribine reached at the end of the induction period is from about 1.5 mg/kg to about 3.5 mg/kg; (ii) a Cladribine-free period wherein no Cladribine is administered; (iii) a maintenance period wherein Cladribine is administered and wherein the total dose of Cladribine administered during the maintenance period is lower than or equal to the total dose of Cladribine reached at the end of the induction period (i); and (iv) a Cladribine-free period wherein no Cladribine is administered; wherein the combined duration of the induction period (i) with the Cladribine-free period (ii) is about 1 year and: a) the duration of the induction period (i) is about 4 months and the duration of the Cladribine-free period (ii) is about 8 months; b) the duration of the induction period (i) is about 2 months and the duration of the Cladribine-free period (ii) is about 10 months; or c) the duration of the induction period (i) is up to 4 months and the duration of the Cladribine-free period (ii) is up to 8 months. 2. The method according to claim 1, wherein the total dose of Cladribine reached at the end of the induction period (i) is from about 1.7 mg/kg to about 3.5 mg/kg. 3. The method according to claim 1, wherein the combined duration of the induction period (i) with the Cladribine-free period (ii) is about 1 year and the total dose of Cladribine reached at the end of this year of treatment is about 1.7 mg/kg or about 3.5 mg/kg. 4. The method according to claim 1, wherein the combined duration of the maintenance period (iii) with the Cladribine-free period (iv) is about 1 year. 5. The method according to claim 4, wherein the duration of the maintenance period (iii) is about 2 months and the duration of the Cladribine-free period (iv) is about 10 months. 6. The method according to claim 4, wherein the combined duration of the maintenance period (iii) with the Cladribine-free period (iv) is about 1 year and the total dose of Cladribine administered during this year of treatment is about 1.7 mg/kg. 7. The method according to claim 1, wherein the combined duration of the induction period (i), the Cladribine-free period (ii), the maintenance period (iii) and the Cladribine-free period (iv) is about 2 years. 8. The method according to claim 7, wherein: the duration of the induction period (i) is about 4 months, the duration of the Cladribine-free period (ii) is about 8 months, the duration of the maintenance period (iii) is about 2 months and the duration of the Cladribine-free period (iv) is about 10 months; or the duration of the induction period (i) is about 2 months, the duration of the Cladribine-free period (ii) is about 10 months, the duration of the maintenance period (iii) is about 2 months and the duration of the Cladribine-free period (iv) is about 10 months. 9. The method according to claim 7, wherein the combined duration of the induction period (i) and the Cladribine-free period (ii) is about 1 year, the combined duration of the maintenance period (iii) and the Cladribine-free period (iv) is about 1 year, the total dose of Cladribine administered during the first year of treatment is about 1.7 mg/kg and the total dose of Cladribine administered during the second year of treatment is about 1.7 mg/kg. 10. The method according to claim 7, wherein the combined duration of the induction period (i) and the Cladribine-free period (ii) is about 1 year, the combined duration of the maintenance period (iii) and the Cladribine-free period (iv) is about 1 year, the total dose of Cladribine administered during the first year of treatment is about 3.5 mg/kg and the total dose of Cladribine administered during the second year of treatment is about 1.7 mg/kg. 11. The method according to claim 1, wherein steps (iii) to (iv) are repeated one, two or three times. 12. The method according to claim 1, wherein the bioavailability of Cladribine is about 40%. 13. The method according to claim 1, wherein the total effective dose of Cladribine reached at the end of the induction period (i) is about 0.7 mg/kg or about 1.4 mg/kg. 14. The method according to claim 1, wherein the total effective dose of Cladribine administered during the maintenance period (iii) is about 0.7 mg/kg. 15. The method according to claim 1, wherein Cladribine is administered from 4 to 7 days per month during the induction period (i). 16. The method according to claim 15, wherein Cladribine is administered from day 1 to day 5 each month during the induction period (i). 17. The method according to claim 15, wherein Cladribine is administered at a daily dose of about 0.175 mg/kg during the induction period (i). 18. The method according to claim 1, wherein Cladribine is administered from 4 to 7 days per month during the maintenance period (iii). 19. The method according to claim 18, wherein Cladribine is administered from day 1 to day 5 each month during the maintenance period (iii). 20. The method according to claim 18, wherein Cladribine is administered at a daily dose of about 0.175 mg/kg during the maintenance period (iii). 21. The method according to claim 1, wherein IFN-beta is administered simultaneously, separately or sequentially with oral Cladribine. 22. The method according to claim 21, wherein IFN-beta is administered simultaneously with oral Cladribine. 23. The method according to claim 22, wherein IFN-beta is administered during the induction period (i), the maintenance period (iii) and the Cladribine-free periods (ii) and (iv). 24. The method according to claim 23, wherein IFN-beta is administered before the induction period (i), during the induction period (i), during the maintenance period (iii), during the Cladribine-free periods (ii) and (iv) and after the Cladribine-free period (iv). 25. The method according to claim 21, wherein the IFN-beta is administered subcutaneously or intramuscularly. 26. The method according to claim 25, wherein the IFN-.beta. is administered at 44 mcg subcutaneously three times a week. 27. The method according to claim 1, wherein the conventional therapy is selected from the group consisting of: treatment with treatment with Glatiramer Acetate, treatment with natalizumab, and treatment with Mitoxantrone. 28. The method according to claim 1, wherein the conventional therapy is treatment with beta interferon. 29. The method according to claim 1, wherein the refractory patients to be treated have experienced at least one relapse in spite of receiving at least one conventional therapy. 30. The method according to claim 29, wherein the at least one relapse occurred during the year prior the beginning of the treatment. 31. The method according to claim 30, wherein the patients to be treated have experienced at least one relapse during the year preceding the beginning of the treatment and have been treated with 12 MIU (44 mcg) of IFN-.beta. three times a week. 32. The method according to claim 1, wherein the refractory patients to be treated have acquired enhanced lesion number or enhanced brain lesion volume in the CNS as detected using methods such as MRI technique. 33. The method according to claim 32, wherein the enhanced lesion number or enhanced brain lesion volume occurred during the year prior to the beginning of the treatment. 34. The method according to claim 33, wherein the patients to be treated have acquired enhanced lesion number or enhanced brain lesion volume in the CNS during the year. 35. The method according to claim 1, wherein the refractory patients to be treated have experienced at least one relapse and have developed increasing disability because of progressive forms of the disease. 36. The method according to claim 1, wherein the refractory patients to be treated are suffering from worsening MS, secondary progressive MS, progressive remitting MS or worsening relapsing-remitting MS. 37. The method according to claim 1, wherein the combined duration of the induction period (i) with the Cladribine-free period (ii) is about 1 year and the duration of the induction period (i) is about 2 months and the duration of the Cladribine-free period (ii) is about 10 months. 38. The method according to claim 1, wherein the combined duration of the induction period (i) with the Cladribine-free period (ii) is about 1 year and the duration of the induction period (i) is up to 4 months and the duration of the Cladribine-free period (ii) is up to 8 months. 39. The method according to claim 1, wherein the combined duration of the induction period (i) with the Cladribine-free period (ii) is 1 year and the duration of the induction period (i) is 4 months and the duration of the Cladribine-free period (ii) is 8 months. 40. The method according to claim 1, wherein said IFN-.beta. is IFN-.beta.1a or IFN-.beta.1b.

Details for Patent 9,925,151

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	BETASERON	interferon beta-1b	For Injection	103471	07/23/1993		2026-05-24
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	05/17/1996		2026-05-24
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	05/28/2003		2026-05-24
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	02/27/2012		2026-05-24
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	03/07/2002		2026-05-24